Quantum Biopharma (NASDAQ:QNTM – Get Free Report) and Imunon (NASDAQ:IMNN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.
Volatility & Risk
Quantum Biopharma has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Imunon has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.
Earnings & Valuation
This table compares Quantum Biopharma and Imunon”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum Biopharma | N/A | N/A | -$26.17 million | ($8.25) | -0.46 |
| Imunon | N/A | N/A | -$14.49 million | ($5.16) | -0.35 |
Quantum Biopharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for Quantum Biopharma and Imunon, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Imunon | 1 | 0 | 1 | 0 | 2.00 |
Imunon has a consensus price target of $10.00, suggesting a potential upside of 458.66%. Given Imunon’s stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Quantum Biopharma.
Profitability
This table compares Quantum Biopharma and Imunon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum Biopharma | N/A | -941.54% | -224.41% |
| Imunon | N/A | -341.23% | -153.79% |
Insider and Institutional Ownership
1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Imunon beats Quantum Biopharma on 10 of the 11 factors compared between the two stocks.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
